WhiteFiber, Inc. Announces Details for Q3 2025 Earnings Conference Call
NEW YORK, Nov. 6, 2025 /PRNewswire/ — WhiteFiber, Inc. (NASDAQ: WYFI), a leading provider of AI infrastructure and HPC solutions, today announced that it will... Read more.
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American exchange... Read more.
DeFi Technologies Reports an Arbitrage Trade of $3.2 Million by DeFi Alpha
Arbitrage Trade Execution: DeFi Alpha, DeFi Technologies’ specialized arbitrage trading desk, generated a one-time return of approximately $3.2 million from... Read more.
Nova Reports Record Third Quarter 2025 Financial Results
REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ — Nova (NASDAQ: NVMI) today announced financial results for the third quarter, the three-month period ended September... Read more.
Continuum Recovery Center of Colorado Selects the Janus Contingency Management Platform to Strengthen Addiction Treatment Services
BOSTON, Nov. 6, 2025 /PRNewswire/ — Continuum Recovery Center of Colorado (CRC), a leading Denver-based outpatient addiction treatment provider, announced... Read more.
Generate Capital Raises over $1 Billion to Expand Infrastructure Credit Solutions
SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Generate Capital (“Generate”), a leading sustainable infrastructure investment platform, today announced... Read more.
Callan Publishes Asset Manager Sustainable Investment Practices Study
Findings show how asset managers integrate sustainability factors into their investment processes SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Callan, a leading... Read more.
MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
-First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage... Read more.
Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
DOVER, Del., Nov. 6, 2025 /PRNewswire/ — Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory... Read more.
ATDev Joins $41 Million ARPA-H Initiative to Build the Future of Robotic Mobility and Independence
PITTSBURGH, Nov. 6, 2025 /PRNewswire/ — Assistive Technology Development, Inc. (ATDev) announced today that it is a subcontractor for the Robotic Assistive... Read more.